Vardenafil Hydrochloride Tablet
Product Images NDC 42291-826

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 42291-826). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (826 30)

The packaging label for Vardenafil Hydrochloride Tablets, 5 mg, by AvKARE. The label indicates a package size of 30 tablets, marked as Rx Only. Storage instructions recommend keeping the product at 25°C with allowable excursions between 15°-30°C. It includes dosage advice to take one tablet daily and safety warnings to keep out of reach of children.*

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical structure diagram of vardenafil hydrochloride, showing its molecular framework including multiple ring systems and functional groups, along with annotations indicating the presence of hydrochloride and trihydrate (3H2O) components.*

FDA Label Image

Figure 1 (Vardenafil Figure 2)

A set of three line graphs illustrating mean maximal changes in systolic blood pressure, diastolic blood pressure, and heart rate relative to timing of Vardenafil treatment pre-nitroglycerin (NTG). The graphs show changes at 24 hours, 8 hours, 4 hours, and 1 hour intervals prior to NTG administration, with error bars indicating variability in the measurements.*

FDA Label Image

Figure 2 (Vardenafil Figure 3)

A line graph showing mean change in mmHg over time (hours) comparing placebo and Vardenafil 5 mg under two conditions: simultaneous administration and 6-hour separation. The graph plots data points from 0 to 6 hours, illustrating different trends in blood pressure changes for each condition and treatment group.*

FDA Label Image

Figure 3 (Vardenafil Figure 4)

Line graph showing the mean change in mmHg over 6 hours for Vardenafil 5 mg and placebo under two conditions: simultaneous administration and 6-hour separation. The y-axis represents mean change in mmHg, and the x-axis represents time in hours. Vardenafil (both conditions) shows a negative mean change, while placebo shows a positive or less negative change over time.*

FDA Label Image

Figure 4 (Vardenafil Figure 5)

A line graph showing mean change in mmHg over time (hours) comparing placebo and Vardenafil at 10 mg and 20 mg doses across two study stages. The graph includes data points and trend lines for placebo (Stage 1 and 2) and Vardenafil (10 mg and 20 mg), with mean changes plotted from 0 to 6 hours.*

FDA Label Image

Figure 5 (Vardenafil Figure 6)

A line graph showing mean change in mmHg over time (0 to 6 hours) comparing placebo and vardenafil at 5 mg and 10 mg doses during two stages. The graph depicts multiple lines with different markers indicating changes for placebo (stage 1 and 2) and vardenafil (5 mg and 10 mg), with some fluctuations below and above zero mean change in mmHg.*

FDA Label Image

Figure 6 (Vardenafil Figure 7)

A line graph illustrating the mean change in blood pressure (mmHg) over 6 hours with various treatments involving Terazosin, including placebo and Vardenafil at 10 mg and 20 mg doses. Two conditions are compared: 6-hour separation and simultaneous administration, with time on the x-axis and mean change on the y-axis.*

FDA Label Image

Figure 7 (Vardenafil Figure 8)

A line graph titled 'TAMSULOSIN' showing mean change in blood pressure (mmHg) on the y-axis versus time in hours on the x-axis. It compares placebo, 10 mg Vardenafil, and 20 mg Vardenafil under 6-hour separation and simultaneous administration conditions, displaying multiple lines with markers depicting changes over 6 hours.*

FDA Label Image

Figure 8 (Vardenafil Figure 9)

A pharmacokinetic line graph showing plasma concentration (µg/L) of a drug over time (hours). The graph depicts a peak in concentration shortly after administration, followed by a gradual decline to near zero by 24 hours. Error bars indicate variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.